Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(17):1178-1179; doi:10.1093/jnci/djj382
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Whitworth, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitworth, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

NCI Launches an Innovative Design for a Breast Cancer Clinical Trial

Ariel Whitworth

The first 10% of the full text of this article appears below.

A new clinical trial will use a comprehensive genetic profile to test whether early-stage breast cancer patients need chemotherapy.

The National Cancer Institute–sponsored trial is among the first to tailor a patient's therapy to her individual genetic profile. Many researchers say this as yet unproven approach is a logical step in cancer treatment.

"It's very different. It's very novel because it's really testing a signature for a certain stratification of patients. It's the first time this has really been done in a treatment trial," said James W. Jacobson, Ph.D., of NCI in Bethesda, Md.

Designed to evaluate whether women with lymph node–negative, estrogen receptor . . . [Full Text of this Article]

From Past to Present

Moving Forward


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?